share_log

Redhill Biopharma | 424B3: Prospectus

Redhill Biopharma | 424B3: Prospectus

Redhill Biopharma | 424B3:募資說明書
美股SEC公告 ·  08/07 09:56
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., an Israeli-incorporated company, has announced a change in the ratio of its Shares per American Depositary Share (ADS), effective August 22, 2024. The new ratio will be one ADS to ten thousand shares, a significant increase from the previous four hundred shares per ADS. This change was filed under Rule 424(b)(3) with the file number 333-268713. The Bank of New York Mellon, acting as the depositary, certifies ownership of the ADSs, which are now adjusted to represent 10,000 deposited ordinary shares of RedHill Biopharma. The detailed terms and conditions of the American Depositary Receipts (ADRs) are set forth in the deposit agreement dated December 26, 2012, which outlines the rights and obligations of the ADS owners and the depositary. The agreement also...Show More
RedHill Biopharma Ltd., an Israeli-incorporated company, has announced a change in the ratio of its Shares per American Depositary Share (ADS), effective August 22, 2024. The new ratio will be one ADS to ten thousand shares, a significant increase from the previous four hundred shares per ADS. This change was filed under Rule 424(b)(3) with the file number 333-268713. The Bank of New York Mellon, acting as the depositary, certifies ownership of the ADSs, which are now adjusted to represent 10,000 deposited ordinary shares of RedHill Biopharma. The detailed terms and conditions of the American Depositary Receipts (ADRs) are set forth in the deposit agreement dated December 26, 2012, which outlines the rights and obligations of the ADS owners and the depositary. The agreement also specifies the procedures for the surrender, transfer, and withdrawal of the deposited securities. The depositary has the right to amend the form of the Receipts and any provisions of the deposit agreement as necessary, with certain amendments requiring a 30-day notice to the ADS owners. The company has also made provisions for the distribution of dividends, voting rights, and other corporate actions to the ADS owners, subject to the terms of the deposit agreement.
以色列公司RedHill Biopharma Ltd.宣佈,自2024年8月22日起,其每個美國存托股票(ADS)所代表的股份比例將發生變化。新比率爲1 ADS 對應1萬股,相較之前每個ADS 代表的400股有了顯著增加。根據文件號爲333-268713的424(b)(3)條款,該變化已記錄。作爲託管方的紐約梅隆銀行證明了ADS的所有權,這些ADS現已調整爲代表RedHill Biopharma的10,000股普通股。美國存託憑證(ADRs)的詳細條款和條件已在2012年12月26日的存款協議中規定,該協議概述了ADS持有人和託管人的權利和義務。該協議還規定了存款證券的放棄、轉讓和退出程序。託管方有權根據需要修改存款憑證的形式和任何存款協議的條款,某些修改需要向ADS持有人提前30天通知。該公司還爲向ADS持有人分配股息、投票權和其他公司行動做了規定,但需遵守存款協議的規定。
以色列公司RedHill Biopharma Ltd.宣佈,自2024年8月22日起,其每個美國存托股票(ADS)所代表的股份比例將發生變化。新比率爲1 ADS 對應1萬股,相較之前每個ADS 代表的400股有了顯著增加。根據文件號爲333-268713的424(b)(3)條款,該變化已記錄。作爲託管方的紐約梅隆銀行證明了ADS的所有權,這些ADS現已調整爲代表RedHill Biopharma的10,000股普通股。美國存託憑證(ADRs)的詳細條款和條件已在2012年12月26日的存款協議中規定,該協議概述了ADS持有人和託管人的權利和義務。該協議還規定了存款證券的放棄、轉讓和退出程序。託管方有權根據需要修改存款憑證的形式和任何存款協議的條款,某些修改需要向ADS持有人提前30天通知。該公司還爲向ADS持有人分配股息、投票權和其他公司行動做了規定,但需遵守存款協議的規定。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息